
Solvonis reports positive data advancing alcohol use disorder drug to Phase 2b trial in the US.
Solvonis Therapeutics announced positive pharmacokinetic data for its SVN-002 program, repurposing J&J's esketamine for moderate to severe alcohol use disorder. The data show comparable drug exposure via sublingual and buccal delivery to the approved...


